Gynecology Cancer Clinical Trials

The most recent listing of current clinical trials for gynecological cancers — including cervix, endometrium, ovarian, vulva and vagina — appears below.  

Site: Gynecology (Includes Cervix, Endometrium,Ovarian, Vulva and Vagina)

Protocol ID    Title

EMBRACE
   A European Study on MRI-Guided Brachytherapy in Locally Advanced Cervical Cancer

GOG-0212
   A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paxlitaxel or CT-2103 (IND #70177) versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Response to Primary Platinum/Taxane Chemotherapy

GOG-0213
   A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone in Combination with Bevacizumab (NSC #704965, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer

GOG-0225
   Can Diet and Exercise Modulate Ovarian, Fallopian Tube or Peritoneal Cancer Progression-Free Survival

GOG-0244-LEG
   The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients

GOG-0258
   A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma

GOG-0263
   Randomized Phase III Clinical Trial Of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy And Pelvic Lymphadenectomy

GOG-0273    Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

GOG-0274/OUTBACK
   A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: the OUTBACK TRIAL

GOG-0277
   A Phase III Randomized Trial of Gemcitabine (NSC # 613327) plus Docetaxel (NSC # 628503) followed by Doxorubicin (NSC # 123127) versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma

GOG-3004
   A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy

GOG-9928
   A Phase I Study of Intraperitoneal Egen-001 Administered in Combination With Pegylated Liposomal-Doxorubicin in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

IIT-UYAR-TCELL
   T Regulatory Cells in Early Endometrial Cancer Before and After Treatment

MERCK-MK-1775-GYN
   A Study of MK-1775 in Combination with Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer